{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:55:12Z","timestamp":1781502912002,"version":"3.54.1"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Genitourinary cancers represent a significant global health burden, accounting for millions of new cases annually and high mortality, particularly in advanced disease. Conventional therapies such as surgery, chemotherapy, radiotherapy, and immune checkpoint inhibitors have improved outcomes but are often limited by resistance, tumor immune evasion, and treatment-related toxicities. Oncolytic viruses, with their dual capacity to directly lyse tumor cells and stimulate systemic anti-tumor immunity, have emerged as a promising therapeutic platform in genitourinary oncology. This review provides a comprehensive analysis of the mechanistic underpinnings of oncolytic viruses\u2019 therapy, encompassing direct oncolysis, immunogenic cell death, modulation of the tumor microenvironment, and genetic engineering strategies. We highlight key viral platforms, landmark clinical advances, and future perspectives in personalized therapies, CRISPR-based genetic engineering, and biomarker-driven clinical translation. Taken together, the integration of oncolytic viruses into genitourinary cancer management represents a rapidly maturing field, with the potential to transform current therapeutic paradigms through tumor-selective viro-immunotherapy.<\/jats:p>","DOI":"10.3389\/fcell.2026.1830852","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:34:03Z","timestamp":1781501643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The emerging role of oncolytic virotherapy in genitourinary malignancies"],"prefix":"10.3389","volume":"14","author":[{"given":"Juliana","family":"Baboghlian","sequence":"first","affiliation":[{"name":"UroScience, School of Medical Sciences, University of Campinas (UNICAMP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Vohra","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Vidyalankar Institute of Technology","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Assoni","sequence":"additional","affiliation":[{"name":"UroScience, School of Medical Sciences, University of Campinas (UNICAMP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S.","family":"Folguieri","sequence":"additional","affiliation":[{"name":"UroScience, School of Medical Sciences, University of Campinas (UNICAMP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Z.","family":"Rocha","sequence":"additional","affiliation":[{"name":"UroScience, School of Medical Sciences, University of Campinas (UNICAMP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Henrique","family":"Amorim","sequence":"additional","affiliation":[{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]},{"name":"Western Bahia Virology Institute, Center of Biological Sciences and Health, Federal University of Western Bahia","place":["Barreiras, Bahia, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]},{"name":"Department of Urology, Comprehensive Cancer Center, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Department of Urology, Lazarski University","place":["Warsaw, Poland"]},{"name":"Department of Urology, Weill Cornell Medical College","place":["New York, NY, United States"]},{"name":"Department of Urology, University of Texas Southwestern","place":["Dallas, TX, United States"]},{"name":"College of Medical Health Technologies, Al-Turath University","place":["Baghdad, Iraq"]},{"name":"Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University","place":["Amman, Jordan"]},{"name":"Karl Landsteiner Institute of Urology and Andrology","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[{"name":"UroScience, School of Medical Sciences, University of Campinas (UNICAMP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT-UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer","place":["S\u00e3o Paulo, Brazil"]},{"name":"ImmunOncology, Pontifical Catholic University of Campinas (PUC-Campinas)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/v16121933","article-title":"Vesicular stomatitis virus: insights into pathogenesis, immune evasion, and technological innovations in oncolytic and vaccine development","volume":"16","author":"Ahmed","year":"2024","journal-title":"Viruses"},{"key":"B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.2967\/jnumed.125.270317","article-title":"Combining PSMA-targeted radiopharmaceutical therapy with immunotherapy","volume":"66","author":"Altunay","year":"2025","journal-title":"J. Nucl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: from mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/v14122641","article-title":"Measles virus-induced host immunity and mechanisms of viral evasion","volume":"14","author":"Amurri","year":"2022","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ymthe.2018.05.015","article-title":"Age-related impaired efficacy of bone marrow cell therapy for myocardial infarction reflects a decrease in B lymphocytes","volume":"26","author":"An","year":"2018","journal-title":"Mol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-Targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.omto.2022.09.003","article-title":"Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer","volume":"27","author":"Araki","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1710038","DOI":"10.3389\/fonc.2025.1710038","article-title":"Tumor innervation and mitochondrial transfer in the cancer pathogenesis: perspectives on genitourinary malignancies","volume":"15","author":"Assoni","year":"2026","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11307-026-02085-w","article-title":"Comparison of [18F]FDG and [18F]PSMA-1007 PET\/CT in the evaluation of muscle-invasive bladder cancer: a pilot feasibility study","volume":"28","author":"Avilez","year":"2026","journal-title":"Mol. Imaging Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.3390\/cancers14215295","article-title":"The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy","volume":"14","author":"Baker","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S36623","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"47","author":"Bell","year":"2013","journal-title":"Oncolytic Virother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/ijms22115738","article-title":"HSV-1 and endogenous retroviruses as risk factors in demyelination","volume":"22","author":"Bello-Morales","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Berry","year":"2008","journal-title":"Prostate"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.immuni.2025.10.013","article-title":"Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma","volume":"58","author":"Bi","year":"","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2025.5838","article-title":"Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors","volume":"68","author":"Bi","year":"","journal-title":"Int. J. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-Unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/OV.S59640","article-title":"The emerging therapeutic potential of the oncolytic immunotherapeutic pexa-vec (JX-594)","volume":"25","author":"Breitbach","year":"2015","journal-title":"Oncolytic Virother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1158\/2767-9764.crc-24-0439","article-title":"Peripheral blood IFN responses to toll-like receptor 1\/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipuleucel-T","volume":"4","author":"Brown","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10637-015-0216-8","article-title":"The oncolytic virus, pelareorep, as a novel anticancer agent: a review","volume":"33","author":"Chakrabarty","year":"2015","journal-title":"Invest. New Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2377830","DOI":"10.1080\/2162402x.2024.2377830","article-title":"Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment","volume":"13","author":"Chatelain","year":"2024","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41580-021-00430-1","article-title":"Cellular origins of dsRNA, their recognition and consequences","volume":"23","author":"Chen","year":"2022","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1090429","DOI":"10.3389\/fimmu.2022.1090429","article-title":"Manipulating T-cell metabolism to enhance immunotherapy in solid tumor","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3390\/ijms27052441","article-title":"Radiation-induced immune modulation and inflammatory responses in human cells and tissues","volume":"27","author":"Chen","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/jco.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.cir-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1038\/s41591-024-03260-8","article-title":"Author correction: targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"30","author":"Choueiri","year":"2024","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","article-title":"Overcoming physical stromal barriers to cancer immunotherapy","volume":"11","author":"Chung","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s43856-025-00786-x","article-title":"Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal Cascade","volume":"5","author":"Chung","year":"2025","journal-title":"Commun. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"188526","DOI":"10.1016\/j.bbcan.2021.188526","article-title":"Delivery routes matter: safety and efficacy of intratumoral immunotherapy","volume":"1875","author":"De Lombaerde","year":"2021","journal-title":"Biochimica Biophysica Acta (BBA) - Rev. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1100317","DOI":"10.3389\/fgene.2022.1100317","article-title":"An IFN-\u03b3-related signature predicts prognosis and immunotherapy response in bladder cancer: results from real-world cohorts","volume":"13","author":"Deng","year":"2023","journal-title":"Front. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1200\/jco.2025.43.16_suppl.5000","article-title":"Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"43","author":"DeWeese","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","article-title":"A balancing act: MDA5 in antiviral immunity and autoinflammation","volume":"27","author":"Dias Junior","year":"2019","journal-title":"Trends Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B46","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.18632\/oncotarget.24263","article-title":"A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209","volume":"9","author":"Eigl","year":"2018","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","article-title":"Measles virus as an oncolytic immunotherapy","volume":"13","author":"Engeland","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/mt.2015.49","article-title":"Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques","volume":"23","author":"Evgin","year":"2015","journal-title":"Mol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/cells15050393","article-title":"Oncolytic viruses in cancer immunotherapy: from molecular engineering to clinical translation","volume":"15","author":"Fayyad-Kazan","year":"2026","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.7150\/jca.102285","article-title":"Oncolytic virus therapy in a new era of immunotherapy, enhanced by combination with existing anticancer therapies: turn up the heat","volume":"16","author":"Fretwell","year":"2025","journal-title":"J. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/mt.sj.6300120","article-title":"Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer","volume":"15","author":"Freytag","year":"","journal-title":"Mol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year Follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"","journal-title":"Mol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncology*Biology*Physics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.can-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0271339","DOI":"10.1371\/journal.pone.0271339","article-title":"Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients","volume":"17","author":"Gillezeau","year":"2022","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.3390\/ijms20205201","article-title":"Enterovirus-associated hand-foot and mouth disease and neurological complications in Japan and the rest of the world","volume":"20","author":"Gonzalez","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","article-title":"Molecular characterization of type I IFN-Induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance","volume":"23","author":"Green","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1629","article-title":"Prostate cancer clinical trials in low- and middle-income countries","volume":"17","author":"Halaseh","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1158\/1078-0432.ccr-10-0054","article-title":"Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.18632\/oncotarget.28723","article-title":"Advancements in bladder cancer treatment: the synergy of radiation and immunotherapy","volume":"16","author":"Hasan","year":"2025","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e010675","DOI":"10.1136\/jitc-2024-010675","article-title":"Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype","volume":"13","author":"Hatami","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/v16060870","article-title":"Vaccinia virus: mechanisms supporting immune evasion and successful long-term protective immunity","volume":"16","author":"Hsu","year":"2024","journal-title":"Viruses"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.3390\/jcm11236997","article-title":"Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects","volume":"11","author":"Hu","year":"2022","journal-title":"J. Clin. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1128\/JVI.73.8.6319-6326.1999","article-title":"Attenuated, replication-competent Herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman Primates","volume":"73","author":"Hunter","year":"1999","journal-title":"J. Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14737159.2025.2573459","article-title":"Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook","volume":"25","author":"Inoue","year":"2025","journal-title":"Expert Rev. Mol. diagn."},{"key":"B72","doi-asserted-by":"publisher","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-Targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"110285","DOI":"10.1016\/j.isci.2024.110285","article-title":"VHL loss enhances antitumor immunity by activating the anti-viral DNA-Sensing pathway","volume":"27","author":"Jiao","year":"2024","journal-title":"iScience"},{"key":"B74","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/1078-0432.ccr-20-2385","article-title":"Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer","volume":"27","author":"Jiffry","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - an updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B77","doi-asserted-by":"publisher","first-page":"834841","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene laherparepvec: moving from first-in-class to best-in-class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.ymthe.2020.03.014","article-title":"Targeted metabolic reprogramming to improve the efficacy of oncolytic virus therapy","volume":"28","author":"Kennedy","year":"2020","journal-title":"Mol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/blc-200404","article-title":"Revisiting an old conundrum: a systematic review and meta-analysis of intravesical therapy for treatment of urothelial carcinoma of the prostate","volume":"7","author":"Kokorovic","year":"2021","journal-title":"Bladder Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"117194","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1038\/s41598-022-10724-9","article-title":"Interferon-\u03b3 increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer","volume":"12","author":"Korentzelos","year":"2022","journal-title":"Sci. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1007\/s11033-021-06752-9","article-title":"Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets","volume":"48","author":"Kumar","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2023.01.002","article-title":"Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models","volume":"28","author":"Kuryk","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: from a \u201cCold\u201d Tumor to a \u201cHot\u201d prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/biomedicines11041071","article-title":"Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomedicines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ymthe.2004.08.028","article-title":"Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer","volume":"10","author":"Lee","year":"2004","journal-title":"Mol. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e006024","DOI":"10.1136\/jitc-2022-006024","article-title":"Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13578-021-00688-0","article-title":"Metabolic reprogramming and metabolic sensors in KSHV-Induced cancers and KSHV infection","volume":"11","author":"Li","year":"2021","journal-title":"Cell. Biosci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2118210","DOI":"10.1080\/2162402x.2022.2118210","article-title":"CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy","volume":"11","author":"Li","year":"","journal-title":"Oncoimmunology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1200\/jco.2022.40.16_suppl.4597","article-title":"CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)","volume":"40","author":"Li","year":"","journal-title":"J. Clin. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-Unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41419-026-08607-2","article-title":"The cGAS-STING pathway in cancer: friend or foe","volume":"17","author":"Li","year":"2026","journal-title":"Cell. Death Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid\u2010derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.2147\/jir.s334041","article-title":"Development of an interferon gamma response-related signature for prediction of survival in clear cell renal cell carcinoma","volume":"14","author":"Liu","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B97","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell. Death Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A phase II study of REOLYSIN\u00ae (Pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell."},{"key":"B100","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.3390\/ijms262311271","article-title":"Targeting DNA damage response and immune crosstalk in cancer: mechanistic insights and therapeutic opportunities","volume":"26","author":"Marcut","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J. Clin. Investigation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3389\/fimmu.2018.01679","article-title":"Radiation-induced transformation of immunoregulatory networks in the tumor stroma","volume":"9","author":"Martinez-Zubiaurre","year":"2018","journal-title":"Front. Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1172\/JCI9744","article-title":"Conditionally replicating herpes vectors for cancer therapy","volume":"105","author":"Martuza","year":"2000","journal-title":"J. Clin. Investigation"},{"key":"B105","volume-title":"World Bank Country Classifications by Income Level for 2024-2025","author":"Metreau","year":"2024"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e005640","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"118.e15","DOI":"10.1016\/j.urolonc.2025.10.023","article-title":"Real-world outcomes of nadofaragene firadenovec for BCG-Unresponsive non\u2013muscle-invasive bladder cancer: a multicenter experience","volume":"44","author":"Moyer","year":"2026","journal-title":"Urologic Oncol. Seminars Orig. Investigations"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e004935","DOI":"10.1136\/jitc-2022-004935","article-title":"Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry","volume":"10","author":"Nguyen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2024","journal-title":"Oncology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/biomedicines10010173","article-title":"Systemic injection of oncolytic vaccinia virus suppresses primary tumor growth and lung metastasis in metastatic renal cell carcinoma by remodeling tumor microenvironment","volume":"10","author":"Park","year":"2022","journal-title":"Biomedicines"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1038226","DOI":"10.3389\/fimmu.2022.1038226","article-title":"Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2023","journal-title":"Front. Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12935-024-03238-z","article-title":"PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma","volume":"24","author":"Park","year":"2024","journal-title":"Cancer Cell. Int."},{"key":"B113","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00262-025-04139-4","article-title":"BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy","volume":"74","author":"Park","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1002311","DOI":"10.37349\/etat.2025.1002311","article-title":"Viral infections and immune modulation in bladder cancer: implications for immunotherapy","volume":"6","author":"Pascoal","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pharmthera.2015.06.011","article-title":"The DNA damage response and immune signaling alliance: is it good or bad? Nature decides when and where","volume":"154","author":"Pateras","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41416-022-02085-x","article-title":"Stromal cells in prostate cancer pathobiology: friends or foes?","volume":"128","author":"Pederzoli","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/cancers12113354","article-title":"Oncolytic adenovirus in cancer immunotherapy","volume":"12","author":"Peter","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/cancers17233849","article-title":"Radiation-induced immune responses from the tumor microenvironment to systemic immunity","volume":"17","author":"Png","year":"2025","journal-title":"Cancers (Basel)."},{"key":"B119","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B120","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.ccr-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"189240","DOI":"10.1016\/j.bbcan.2024.189240","article-title":"Kidney cancer: from tumor biology to innovative therapeutics","volume":"1880","author":"Rinaldi","year":"2025","journal-title":"Biochimica Biophysica Acta (BBA) - Rev. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"109364","DOI":"10.1016\/j.intimp.2022.109364","article-title":"Poxviruses and the immune system: implications for monkeypox virus","volume":"113","author":"Saghazadeh","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.cir-21-0171","article-title":"Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e11275","DOI":"10.7554\/eLife.11275","article-title":"Comparative analysis of viral RNA signatures on different RIG-I-like receptors","volume":"5","author":"Sanchez David","year":"2016","journal-title":"Elife"},{"key":"B126","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1128\/JVI.71.6.4736-4743.1997","article-title":"Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry","volume":"71","author":"Shafren","year":"1997","journal-title":"J. Virol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. and Clin. Cancer Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12672-024-01674-x","article-title":"Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer","volume":"15","author":"Shen","year":"2024","journal-title":"Discov. Oncol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-9966-31-47","article-title":"The immunosuppressive factors IL-10, TGF-\u03b2, and VEGF do not affect the antigen-presenting function of CD40-activated B cells","volume":"31","author":"Shimabukuro-Vornhagen","year":"2012","journal-title":"J. Exp. and Clin. Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","article-title":"Systemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21","volume":"113","author":"Skelding","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"B131","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/blc-230083","article-title":"The evolution of nadofaragene firadenovec: a review and the path forward","volume":"10","author":"Steinmetz","year":"2024","journal-title":"Bladder Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1016\/j.annonc.2021.08.1076","article-title":"554P phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients","volume":"32","author":"Tanabe","year":"2021","journal-title":"Ann. Oncol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/0008-5472.can-09-2408","article-title":"Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic","volume":"70","author":"Thirukkumaran","year":"2010","journal-title":"Cancer Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00262-025-04132-x","article-title":"VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function","volume":"74","author":"Tong","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"B135","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/OV.S66045","article-title":"Targeting tumor vasculature through oncolytic virotherapy: recent advances","volume":"169","author":"Toro Bejarano","year":"2015","journal-title":"Oncolytic Virother"},{"key":"B136","doi-asserted-by":"publisher","first-page":"TPS598","DOI":"10.1200\/jco.2022.40.6_suppl.tps598","article-title":"A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)","volume":"40","author":"Uchio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"201128","DOI":"10.1016\/j.omton.2026.201128","article-title":"Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models","volume":"34","author":"van de Merbel","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.ccr-08-0524","article-title":"A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer","volume":"14","author":"Vidal","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/ijc.34139","article-title":"Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy","volume":"151","author":"Wang","year":"2022","journal-title":"Int. J. Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"491621","DOI":"10.3389\/fonc.2020.491621","article-title":"Immune infiltration landscape in clear cell renal cell carcinoma implications","volume":"10","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e12102","DOI":"10.1016\/j.heliyon.2022.e12102","article-title":"Integrated molecular analyses of an interferon-\u03b3 based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification","volume":"8","author":"Wang","year":"","journal-title":"Heliyon"},{"key":"B142","doi-asserted-by":"publisher","first-page":"704999","DOI":"10.3389\/fonc.2021.704999","article-title":"The application of CRISPR\/Cas9 technology for cancer immunotherapy: current status and problems","volume":"11","author":"Wang","year":"","journal-title":"Front. Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1230251","DOI":"10.3389\/fonc.2023.1230251","article-title":"Current status of PSMA-Targeted imaging and therapy","volume":"13","author":"Wang","year":"","journal-title":"Front. Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e007808","DOI":"10.1136\/jitc-2023-007808","article-title":"Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses","volume":"12","author":"Wang","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12672-025-02772-0","article-title":"Trends and hotspots in targeted therapy resistance research for renal cell carcinoma: a bibliometric and visualization analysis","volume":"16","author":"Wang","year":"","journal-title":"Discov. Oncol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"","journal-title":"Mol. Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro. Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro. Oncol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e173934","DOI":"10.1172\/jci173934","article-title":"VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis","volume":"134","author":"Wolf","year":"2024","journal-title":"J. Clin. Investigation"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1200\/jco-25-01346","article-title":"RP1 combined with nivolumab in advanced Anti\u2013PD-1\u2013Failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.trsl.2017.08.004","article-title":"The anticancer functions of RIG-I\u2013like receptors, RIG-I and MDA5, and their applications in cancer therapy","volume":"190","author":"Wu","year":"2017","journal-title":"Transl. Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1142172","DOI":"10.3389\/fcimb.2023.1142172","article-title":"Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.3390\/ijms26146879","article-title":"Strategic advances in targeted delivery carriers for therapeutic cancer vaccines","volume":"26","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.trsl.2024.10.003","article-title":"Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma","volume":"275","author":"Xu","year":"2025","journal-title":"Transl. Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.3390\/curroncol29090526","article-title":"Immunogenic cell death role in urothelial cancer therapy","volume":"29","author":"Yadollahvandmiandoab","year":"2022","journal-title":"Curr. Oncol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41541-025-01219-5","article-title":"Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine","volume":"10","author":"Yamada","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B161","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.mtbio.2025.101963","article-title":"Advancing cancer therapy: nanomaterial-Based encapsulation strategies for enhanced delivery and efficacy of curcumin","volume":"33","author":"Yan","year":"2025","journal-title":"Mat. Today Bio"},{"key":"B162","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13567-025-01691-w","article-title":"Activation of the ATM\u2013Chk2 DNA damage response pathway by Newcastle disease virus enhances viral replication","volume":"57","author":"Yan","year":"2026","journal-title":"Vet. Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/biomedicines10123262","article-title":"Oncolytic adenovirus, a new treatment strategy for prostate cancer","volume":"10","author":"Yang","year":"2022","journal-title":"Biomedicines"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1481296","DOI":"10.3389\/fimmu.2024.1481296","article-title":"Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1450203","DOI":"10.3389\/fphar.2024.1450203","article-title":"Strategies for engineering oncolytic viruses to enhance cancer immunotherapy","volume":"15","author":"Yin","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/17460441.2021.1850689","article-title":"The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?","volume":"16","author":"Zhang","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/ijgc-2022-003914","article-title":"Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer","volume":"33","author":"Zhang","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/vaccines13080880","article-title":"Oncolytic Herpes simplex virus therapy: latest advances, core challenges, and future outlook","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines (Basel)."},{"key":"B169","doi-asserted-by":"publisher","first-page":"101599","DOI":"10.1016\/j.gendis.2025.101599","article-title":"Recent advances in oncolytic virus combined immunotherapy in tumor treatment","volume":"12","author":"Zhou","year":"2025","journal-title":"Genes Dis."},{"key":"B170","doi-asserted-by":"publisher","first-page":"705361","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1830852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:34:05Z","timestamp":1781501645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1830852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":170,"alternative-id":["10.3389\/fcell.2026.1830852"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1830852","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1830852"}}